Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma
Autor: | Debra Rembert, Debra A. Patt, Wan-Yu Tseng, Mark Yap, Christopher A. Yasenchak |
---|---|
Rok vydání: | 2015 |
Předmět: |
Adult
Male Cancer Research Pediatrics medicine.medical_specialty Adolescent medicine.medical_treatment Disease Young Adult Recurrence Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Neoplasm Staging Retrospective Studies Aged 80 and over Chemotherapy business.industry Disease progression Front line Health Care Costs Hematology Middle Aged medicine.disease Hodgkin Disease Oncology Retreatment Disease Progression Physical therapy Hodgkin lymphoma Female Observational study Health Expenditures business Progressive disease Cohort study |
Zdroj: | Leukemia & Lymphoma. 56:3143-3149 |
ISSN: | 1029-2403 1042-8194 |
Popis: | The current study aimed to assess the economic burden of progressive disease among patients with Hodgkin lymphoma (HL) receiving second- or third-line therapy in a large US network of community-based practices. This retrospective, observational cohort analysis used electronic health records to examine adult patients with classical HL who received chemotherapy between 2007 and 2011. Of 291 observations, 112 had non-progressive disease (received only one line of therapy; LOT1), 114 received second-line therapy (LOT2), and 65 received third-line therapy (LOT3). In LOT2, 49 patients (43%) underwent transplant. In LOT3, 13 patients (20%) underwent transplant. The mean total cost per line of therapy was $21 956 in LOT1, $77 219 in LOT2, and $59 442 in LOT3. When transplant was required, the mean total cost per line of therapy increased 7- to 8-fold when compared with the cost of LOT1 (approximately $154 000 for LOT2 and $193 000 for LOT3). Future therapies that intervene as early as possible in the treatment algorithm to prevent or significantly delay relapse will likely result in significant cost savings. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |